Skip to main content

Interleukin-33 Ameliorates Experimental Colitis through Promoting Th2/Foxp3+ Regulatory T-Cell Responses in Mice


Crohn’s disease (CD) is characterized by the activation of Th1 and Th17 cells and deficiency of regulatory T cells (Tregs), leading to intestine tissue injury and destruction. As a novel cytokine of the interleukin (IL)-1 family, the role and underlying mechanisms of IL-33 in CD remain poorly understood. Here, we assess the effects and mechanisms of IL-33 on the trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis that mimics human CD. We found that IL-33 levels were increased in the TNBS-treated mice, whereas recombinant IL-33 (rIL-33) administration substantially ameliorated TNBS-mediated colonic tissue injury and clinical symptoms of colitis. The protective effect of rIL-33 was partly associated with the markedly increased induction of Th2-type cytokines. Importantly, rIL-33 treatment resulted in prominently upregulated Foxp3 expression in the TNBS-treated mice, and depletion of Tregs significantly abrogated the impact of IL-33 on reducing the development of colitis. Notably, the level of CD103+ dendritic cells (DCs), which promotes development of Tregs, is also increased in mesenteric lymph node and lamina propria of rIL-33-treated mice. The impact of rIL-33 on CD103+ DC induction was the result of indirectly upregulating intestine epithelial cells that produce thymic stromal lymphopoietin and retinoic acid but do not directly act on DCs. In conclusion, our data provide clear evidence that IL-33 plays a protective role in TNBS-induced colitis, which is closely related to a Th1-to-Th2/Treg switch. Thus, IL-33 is a promising candidate for the development of new treatments for CD.


Crohn’s disease (CD) and ulcerative colitis are the two major forms of inflammatory bowel disease. Although the etiology of both CD and ulcerative colitis remains to be determined, the imbalanced cytokine production and T-cell dysfunction are considered the key factors in inflammatory bowel disease pathogenesis (1,2). Trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis closely resembles important immunological and histopathological aspects of CD (3), characterized by a predominant Th1/Th17-mediated immune response and mucosal inflammation (4,5).

Interferon (IFN)-γ, most produced by Th1 cells, is the key proinflammatory cytokine in pathological progression of human CD and TNBS-induced experimental colitis. On the contrary, most studies have demonstrated that promoting the Th2 profile can reduce the pathological progression of Th1-mediated colitis (6,7). However, the mechanism with which to accomplish such a switch remains obscure. Recently, imbalance of the development and function of Th1/Th17 and regulatory T cells (Tregs) has been shown to play a critical role in autoimmune diseases (8), including CD and TNBS-induced colitis (9,10).

Interleukin (IL)-33, also known as nuclear factor from high endothelial venules (NF-HEV) and interleukin-1 family member 11 (IL-1F11), was identified as a novel member of the IL-1 family. Previous studies have shown that IL-33 is highly reminiscent of IL-1 a and high-mobility group box 1 (HMGB1), two dual-function proteins that also play important roles as both intracellular nuclear proteins and extracellular cytokines (11). IL-33 is synthesized as a 30-kDa precursor protein and could be cleaved as a mature 18-kDa protein; it was identified as the special ligand for the receptor ST2L (12), which is a selective marker of Th2 cells but not Th1 cells (13,14). Recent studies have shown that IL-33 plays a deleterious role associated with the activation and production of type II cytokines (15,16). However, by switching Th1/Th17 to Th2 type immune response, IL-33 can reduce the development of atherosclerosis and inhibit graft rejection, which are mainly mediated by Th1 and Th17 response (17,18). In addition, IL-33 shows immunomodulatory effects on dendritic cells (DCs) (19), which play a fundamental role in the homeostasis of the gut (20). Moreover, CD103+ DCs, the primary source of indoleamine 2,3-dioxygenase (IDO) in the gut, can be differentiated by retinoic acid, thymic stromal lymphopoietin (TSLP) and transforming growth factor (TGF)-β1 and promote development of Foxp3+ Tregs in mesenteric lymph node (MLN) and lamina propria (21,22).

Although IL-33 levels are elevated in human CD (23,24), the functional relevance of increased IL-33 production during intestine inflammation remains unclear. Our data here show that IL-33 expression is also significantly increased in inflamed tissues of mice with TNBS-induced colitis that resembles the human CD, and recombinant IL-33 (rIL-33) treatment led to a striking improvement in both the clinical and histopathological aspects of the colitis. The mechanisms of the effects predominantly depend on Treg expansion and are partly associated with Th2-type immune bias via upregulating CD103+ DCs and ST2L+ CD4+ T cells.

Materials and Methods

Animals and Cell Lines

Female 6- to 8-wk-old BALB/c mice were purchased from the Institute of Experimental Animal, Chinese Academy of Medical Sciences (Beijing, China). The mice were housed in the specific pathogen-free (SPF) facility at the Tongji Medical College for at least 1 wk before inclusion in experiments. All of the studies were performed in accordance with the Tongji Medical College Animal Care and Use Committee guidelines. The RAW264.7 cell line was obtained from ATCC (Manassas, VA, USA).

Production of Recombinant Mouse IL-33 Protein and Polyclonal Anti-Mouse IL-33 Antibody and Assessment of Their Activity

Expression and purification of mouse rIL-33-glutatione S-transferase (GST) were carried out as previously described (18). Removal of the GST tag and endotoxin and the production of polyclonal anti-mouse IL-33 antibody are described in the supplementary materials. The activity of antibody was confirmed (Supplementary Figure S1).

Induction of Colitis

TNBS-induced mice colitis was induced in female BALB/c mice as described elsewhere (25). Mice were lightly anesthetized, and then 0.1 mL of a 2.5% (w/v) TNBS (Sigma-Aldrich) solution in 50% ethanol was slowly administered into the colon, and 50% ethanol alone served as the control. Mice received control phosphate-buffered saline (PBS) or rIL-33 (2 µg/d), anti-IL-33 (300 µg/d) polyclonal antibody and control IgG diluted in PBS daily by delivering intraperitoneally at the time of TNBS administration until d 4. In the therapeutic model, rIL-33 was injected intraperitoneally into mice from d 2 after TNBS inoculation to d 5. For blockage of IL-4 activity, a neutralizing anti-IL-4 antibody (11B11; Biolegend, San Diego, CA, USA) or control IgG (200 µg/mouse) was given to TNBS-treated mice 1 h before rIL-33 administration. Depletion of regulatory T cells has been previously reported (26) and was confirmed as described in Supplementary Figure S2. Anti-CD25 antibody (PC61; Biolegend) or control IgG (200 ng/mouse) was injected 24 h before IL-33 administration.

Histological and Immunohistochemical Analysis

The mice were sacrificed by cervical dislocation. Macroscopic assessment of inflammation was scored as in a previous study (25). Subsequently, samples of colon tissues were prepared for tissue sections and then stained with hematoxylin and eosin. Histological analysis was performed as described in a previous report (27). Immunohistochemical and immunofluorescence staining was performed by an established technique (28). The sections were stained in PBS containing antibodies against IL-33 and F4/80 (Abcam, Cambridge, MA, USA) and were then incubated with fluorescein isothiocyanate (FITC)- and rhodamine-conjugated secondary antibody and examined by an Olympus confocal microscope.


Colon protein extraction was performed to immunoblot assay conducted as described previously (25). The primary antibody included rabbit anti-IL-33 (Alexis Biochemical, Lausen, Switzerland), rat anti-IL-1R/ST2 (R&D, Minneapolis, MN, USA), rat anti-Foxp3 and rat anti-IDO (Biolegend), rat anti-IFN-γ, rabbit anti-IL-17 and rabbit anti-β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). After incubating with secondary antibody-conjugated horseradish peroxidase, immunoreactivity was developed by an enhanced chemiluminescence system (Pierce).

Quantitative Real-Time Reverse Transcriptase-Polymerase Chain Reaction

Total RNA was extracted from colon tissues or intestine epithelial cells (IECs) and used for analyzing the expression levels of the gene of interest. Details of the procedures used for the quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) are described in the Supplementary Materials and Methods.

Generation of Mouse BMDCs, Isolation of LPMCs and IECs and T-cell/BMDC Coculture

Mouse bone marrow-derived cells (BMDCs) were propagated from bone marrow cells, as described previously (28). All recombinant cytokine in vitro experiments were obtained from Peprotech (London, UK). Lamina propria mononuclear cells (LPMC) and IEC isolation was prepared as described in the Supplementary Materials and Methods. BMDCs were conditioned with supernatants from IECs treated with rIL-33 or PBS. Then the BMDCs were cocultured with 5,6-carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled CD4+CD25 T cells purified by CD4 MACS-negative selection and followed by CD25 MACS-positive selection (Miltenyi Biotech, Bergisch Gladbach, Germany). A soluble anti-CD3 (0.5 µg/mL) was added to the T-cell/BMDC cultural medium. The cells and supernatants were harvested after 5 d.

Flow Cytometry

The MLN lymphocytes, LPMCs and BMDCs were obtained, and the cells were incubated with fluorescence-conjugated monoclonal antibodies in staining buffer. The Foxp3 staining was performed in accordance with the manufacturer’s instructions (eBioscience, San Diego, CA, USA). Antibodies used for flow cytometry were as follows: FITC-conjugated anti-CD4, anti-ST2L; phycoethrin (PE)-labeled anti-CD4 and CD103; allophycocyanin (APC)-labeled CCR7 and Foxp3; and PE/cy7-conjugated CD11c. All antibodies were purchased from ebioscience, except ST2L, which was obtained from MD Bioscience (St. Paul, MN, USA).

Enzyme-Linked Immunosorbent Assay

Blood samples were collected by cardiac puncture and placed at room temperature 30 min before centrifugation. The serum was stored at −80&3°C until analyzed. The MLN lymphocytes of mice were stimulated by anti-CD3/anti-CD28 antibody (eBioscience) in vitro. Then the supernatants were harvested after 72 h culture. The levels of IFN-γ, IL-4, IL-5, IL-10, IL-13 and IL-17 cytokines were determined by enzyme-linked immunosorbent assay (ELISA) kits (eBioscience) according to the manufacturer’s instructions.

Statistical Analysis

The data are presented as means ± standard deviation (SD). Statistical differences were determined by the Student t test. Two-sided probability (p) values <0.05 were considered significant.

All supplementary materials are available online at .


IL-33 Is Upregulated in Th1/Th17-Mediated Murine TNBS-Induced Colitis

In recent studies, increased expression of IL-33 was demonstrated in human CD (23,24). Consistently, in this study, a markedly increased expression of IL-33, IFN-γ and IL-17 was observed in TNBS-induced colitis when compared with the control group (Figures 1A, B). In addition, accompanied by severe colonic tissue destruction in TNBS-treated mice (Figure 1C), an abundance of IL-33 was expressed in the cytoplasm of infiltrated cells in the lamina propria and submucosa, which showed morphological characteristics of macrophages of TNBStreated mice, whereas the colonic epithelial cells showed a slight staining (Figure 1D). Furthermore, we observed that the majority of the IL-33-producing cells in lamina propria and submucosa were F4/80 macrophages by performing immunofluorescence double staining (Figure 1E). In vitro, IL-33 mRNA and protein were present in both the RAW 264.7 cell line and primary peritoneal macrophages (Figure 1F). These data suggest that the major source of IL-33 in colonic tissues of TNBS-treated mice was the infiltrated macrophages.

Figure 1

IL-33 is highly expressed in TNBS-induced colitis. Colonic tissue samples were collected from mice on d 4 after instillation with TNBS or 50% ethanol. (A) Expression of IL-33, IFN-γ and IL-17 proteins in total tissue extracts was assessed by immunoblot. f-IL-33 and c-IL-33 mean precursor of and mature IL-33, respectively. (B) The mRNA expression of IL-33in colonic tissue was analyzed. Data from one representative out of three experiments indicate mean ± SD (n = 5-8/group); #p < 0.01. (C) The colonic tissue sections from the two groups (TNBS and ethanol treatment) were stained with hematoxylin and eosin. (D) The production of IL-33 in colonic tissue was detected by immunohistochemistry (red arrows). (E) The colonic tissue sections from TNBS-treated mice were costained by IL-33 (green) and F4/80 (red) antibody. Colocalization is indicated as yellow (white arrows). (F) IL-33 mRNA and protein expression in peritoneal macrophage and the RAW 264.7 cell line was assessed by RT-PCR and immunoblot. Data shown are representative of three independent experiments.

IL-33 Reduces the Development of Experimental Colitis in Mice

Next, we sought to determine the role of IL-33 in TNBS-induced colitis. rIL-33, PBS, anti-IL-33 antibody or control IgG was given intraperitoneally daily at the time of TNBS administration, respectively. Compared with the PBS, antibody and IgG group, rIL-33-treated mice displayed a markedly lower loss of original weight (p < 0.05) (Figure 2A). In addition, the antibody group exhibited more severe weight loss than the IgG group, although the changes between them were not significant (Figure 2A). Moreover, lower morphological scores and a reduced inflammatory cell infiltration of mucosa and submucosa were observed in rIL-33-treated mice (Figures 2BD). Next, we determined whether IL-33 is therapeutic in TNBS-induced colitis by treating with rIL-33 or PBS on d 2 after TNBS inoculation. In contrast to PBS administration, rIL-33 treatment caused significant weight regain and considerably alleviated inflammation in mice with established colitis (Figures 2E, F). These data clearly indicate that IL-33 potently ameliorated the development and bowel pathology of TNBS-induced colitis.

Figure 2

rIL-33 treatment decreases the severity of TNBS-induced colitis. (A–D) Mice with TNBS-induced colitis were treated with PBS, rIL-33, IgG or anti-IL-33 antibody as described in Materials and Methods. (A) The body weight variations of original weight were recorded on d 4 after the TNBS inoculation. (B) The macroscopic score of the colon was assessed. Data indicate the mean ± SD of all experiments. (C, D) The histology of tissue sections from TNBS-treated mice, as indicated in the above treatment, was analyzed. (E–F) Mice with established colitis with rIL-33 or PBS treatment were also subjected to assess the body weight and histological change. Data indicate mean ± SD (n = 6-8/group); *p < 0.05. All data are representative of one of three independent experiments.

IL-33 Inhibits Th1 and Promotes Th2 Profile in TNBS-Induced Colitis

To explore whether rIL-33-induced amelioration of TNBS-induced colitis correlated with reduction of IFN-γ and IL-17 in TNBS-induced colitis, we analyzed the cytokines of sera and MLN cells from colitis mice treated with PBS or rIL-33. As expected, TNBS-treated mice receiving rIL-33 exhibited markedly decreased expression of IFN-γ and increased Th2-type cytokine production of IL-5 and IL-13 compared with PBS controls (Figures 3A, B). Consistently, similar results were observed in the colonic tissues by real-time PCR analysis (Figure 3C). Moreover, an increased expression of IL-4 protein in colonic tissues, the critical Th2 cytokine for counterregulating Th1 function, was also observed by immunoblot (Supplementary Figure S3A). Unexpected, IL-17 expression was not changed between two groups. Next, we sought to confirm whether the IL-33-induced Th2 immune deviation was correlated with ST2L+CD4+ T cells, which are thought to play an important role in the generation of Th2-type cytokines. As expected, the proportion of CD4+STL2+ in LPMCs and MLN cells of mice treated with rIL-33 was higher when compared with PBS treatment, especially in LPMCs (p < 0.05) (Figure 3D). Taken together, these results indicate that rIL-33 administration of rIL-33 switches Th1 to Th2 immune profile in the mice with TNBS colitis through ST2L+CD4+ T cells.

Figure 3

rIL-33 treatment induces Th2 cytokines and inhibits Th1 cytokines in mice with TNBS-induced colitis. Mice instilled with TNBS were injected intraperitoneally with rIL-33 or PBS daily. The serum, MLN cells and LPMCs were collected from mice killed d 4 after TNBS inoculation. (A) Cytokines (IL-4, IL-5, IL-13, IFN-γ and IL-17) in sera were determined by ELISA (pg/mL). (B) MLN cells were stimulated with α-CD3/α-CD28 and the cultural supernatants were harvested, followed by ELISA analysis of cytokines indicated above (ng/mL). (C) Total mRNA was extracted from colonic tissues to analyze the expression of IL-4, IL-5, IL-13, IFN-γ, IL-17, IL-6, IL-10 and TNF-α by real-time PCR. The data are presented as mean ± SD (n = 6-8/group). (D) MLN cells and LPMCs were obtained at indicated time points and pooled; membrane expression of ST2L in the CD4+ subset was detected by flow cytometry. Data are shown as the mean ± SD (n = 6-8/group) and are representative of three independent experiments; *p < 0.05, #p < 0.01.

IL-33 Induces Regulatory T Cells by Expanding CD103+IDO+ Tolerogenic DCs in Mice with TNBS Colitis

It has been demonstrated that Foxp3+ Tregs reduce the development of TNBS-induced experimental colitis via IL-10 (29). In line with an increased expression of IL-10 (Figure 3C), an increase of Foxp3+ Tregs and IDO expression were observed in IL-33-treated mice with TNBS-induced colitis (Supplementary Figure S3). Interestingly, CD103+ DCs, the primary source of IDO in the gut and involved in Foxp3+ Treg development via IDO (21), were remarkably increased in MLN lymphocytes and LPMCs of IL-33-treated mice (Figures 4AC). As expected, we also observed that CD103+ DCs from MLN highly express IDO and CCR7 and might represent a lamina propria-derived migratory population (Figure 4D). Taken together, these results suggest that IL-33-induced amelioration of colitis might also act through the induction of CD103+IDO+ DCs and development of regulatory T cells.

Figure 4

rIL-33 treatment increases the numbers in the CD103+CD11c+ tolerogenic DC sub-population. MLN cells and LPMCs were isolated from the colitis mice treated with rIL-33 or PBS on d 4 after administration of TNBS (A–C). MLN cells (A) and LPMCs (B) were analyzed by flow cytometry for CD103+CD11c+ DCs (C), and data are presented as the percentage of CD103+CD11c+ cells in total MLN cells (upper panel) or CD11c+ subset (lower panel). Data represent mean ± SD per group (n = 6-8/group). The results shown are from one of three independent experiments. (D) MLN cells from normal mice were collected to analyze the CCR7 and IDO expression in subpopulation by CD103. The mean fluorescence intensity (MFI) of IDO expression in the two subpopulations was recorded by flow cytometry. The data are presented as mean ± SD of four mice investigated; *p < 0.05, #p < 0.01.

IL-33 Indirectly Promotes Development of Tolerogenic CD103+ DCs and Tregs via Activating IECs

To further support our contention that the induction of CD103+ DC and Tregs might be mediated by IL-33, the primary BMDCs were used to investigate the mechanism. Consistently, CD103+ BMDCs were also predominantly expressing IDO. Unexpectedly, rIL-33 has no direct effect on the promotion of CD103+CD11c+ tolerogenic DCs (Supplementary Figure S4). Previous studies have shown that IECs promote gut homeostasis and maintenance of tolerance via educating DC through inducing tolerogenic CD103+ DC subpopulation by TSLP, retinoic acid and TGFβ1 (20,22). Therefore, we hypothesized that IL-33 may indirectly promote the development of CD103+ DCs through activating IECs. As expected, ST2L was expressed on mice primary IECs (Figure 5A), and the IECs from rIL-33-treated mice with TNBS-induced colitis displayed highly increased mRNA expressions of TSLP and aldehyde dehydrogenase 1A1 (ALDH1A1) involved in the conversion of retinal to retinoic acid (Figure 5B). Furthermore, the supernatants of primary IECs from TNBS-treated mice with IL-33 administration significantly promoted the proportion of CD103+ DC differentiation (Figure 5C). Collectively, these results showed that IL-33 treatment indirectly favors the induction of CD103+ DCs, partly through enhancing IECs to produce TSLP and ALDH1A1 but not directly act on DCs.

Figure 5

IL-33 indirectly promotes tolerogenic CD103+ DC development and Treg expansion via activating IECs. (A) Colonic epithelial cells were collected to analyze the ST2L expression by flow cytometry and PCR. (B, C) Colonic epithelial cells were extracted from normal mice, and colitis mice were treated with rIL-33 or PBS on d 4 after TNBS inoculation, followed by total RNA, and cultural supernatants were harvested. TSLP, TGF7#x03B2;1 and ALDH1A1 mRNA was assessed by quantitative real-time PCR (B), and CD103+ expression on BMDCs was analyzed by flow cytometry after incubation with epithelial cells supernantants or culture medium (CM) (C). Data represent mean ± SD per group (n = 6-8/group). The data shown are representative one of three separate experiments. *p < 0.05. (D–F) Colonic epithelial cells of colitis mice were activated with IL-33 24 h or not in vitro. (D) Expression of genes encoding TSLP, TGFβ1 and ALDH1A1 was assessed by quantitative real-time PCR. (E) BMDCs conditioned by supernatants of colonic epithelial cells were subjected to assess expression of CD103. (F) CD4+CD25T cells were cocultured with BMDCs educated by above supernatants or supernatant of epithelial cells from normal mice, followed by analysis of CD4+Foxp3+ differentiation and proliferation response. Results represent mean ± SD. The data shown are representative one of three separate experiments. *p < 0.05.

To further confirm whether IL-33 suppresses the development of TNBS-induced mice through promoting generation of Tregs by expanding CD103+ DCs, we isolated colonic epithelial cells from mice with TNBS-induced colitis and incubated them with rIL-33. Consistent with above results, IL-33-treated IECs remarkably increased expression of TSLP and ALDH1A1 in vitro (Figure 5D), and the supernatants significantly augmented the CD103+ DCs when compared with the PBS group (Figure 5E). Next, we examined whether the induction of the epithelial cell-conditioned DCs have capacity to promote Treg differentiation. As expected, BMDCs conditioned by the supernatants of IL-33-treated IECs markedly promoted Treg differentiation and inhibited T-cell proliferation (Figure 5F).

IL-33-Mediated Reduction of Experimental Colitis Development Mainly Relies on Treg Expansion

Both Th2 deviation and Treg expansion play a protective role in the reduction of TNBS-induced colitis development. Therefore, the roles of Th2 deviation and Treg expansion induced by IL-33 treatment were explored in mice with TNBS-induced colitis. Anti-IL-4 or anti-CD25 antibody was used to neutralize IL-4 activity and deplete CD25+ Tregs, respectively. Specifically, Treg depletion evidently abolished the protective role of IL-33 when compared with the IgG group. Furthermore, anti-IL-4 antibody treatment partly reversed the IL-33 effect (Figure 6). Thus, these data showed that IL-33 reduced the development of TNBS-induced colitis mainly depending on Treg function.

Figure 6

Depletion of Tregs abrogates the protective effect of IL-33 in TNBS-induced colitis. Mice with TNBS-induced colitis were treated with a combination of IL-33 and anti-IL-4 or anti-CD25 antibody; control mice received normal IgG (n = 5 each). (A) The variations in body weight of original weight were recorded on d 4 after TNBS inoculation. (B, C) The histology of tissue sections from TNBS-treated mice with the above treatment was analyzed. Data are mean ± SD; *p < 0.05.


This report is the first to document the role of IL-33 in a mouse model of human CD. Current results provide evidence for a novel mechanism by which IL-33 ameliorates the intestinal inflammation via promoting a switch from intestinal Th1 to Th2/Treg responses.

The dual functions of IL-33 were exhibited in the immune response that acts by binding to the orphan receptor ST2L. A harmful role for IL-33 was established in asthma (30) and autoimmune diseases (3133). In contrast, IL-33 reduces the development of atherosclerosis (17), attenuates sepsis (34) and allows susceptible mice to expel the parasite (35). Indeed, the IL-33/ST2 system also plays a dichotomous role in inflammatory bowel disease pathogenesis (36,37), and the exact role of this axis needs to be further defined. Here, we show that IL-33 was markedly increased in the mice with TNBS-induced colitis, which mimics human CD. Previous studies have also demonstrated that increased expression of IL-33 plays a pathological role in the development of ulcerative colitis (24). Interestingly, rIL-33 treatment had a significant beneficial effect on Th1/Th17-mediated experimental colitis, and there was a deleterious consequence with the anti-IL-33 antibody, although without reaching significance. The reason for this result might be that the endogenous IL-33 in the colonic tissues is induced by TNBS, insignificant in relation to the inflammatory response raised.

Previous work has demonstrated that administration of IL-33 to mice leads to histological changes in the lung and gastrointestinal tract, including increased mucus production, epithelial cells hyperplasia and hypertrophy. The histological changes are expected to be linked to enhanced Th2-type response (12). Conversely, in this study, we found that mice treated with rIL-33 reduced the progression of TNBS-induced pathology. Likewise, TSLP and IL-25, shown to develop Th2 cell-associated immune responses and lead to histological changes in intestine (38), have also exhibited immunoregulatory properties in experimental colitis and human CD (20,39,40). Here, we speculate that an increased expression of IL-33 in infiltrated macrophages may be a cause of self-negative regulation which inhibits the development of colitis. It has been consistently found that macrophage plays a protective role in CD by attraction of granulocytes to the gut wall and clearance of intruding bacteria, among other ways (41).

Numerous studies have shown that the change of the cytokine profile from Th1 to Th2 could ameliorate Th1-mediated disease (7,18). It was previously demonstrated that IL-33 treatment reduces the development of atherosclerosis and prolongs the allograft survival by promoting Th2 differentiation and inhibiting Th1 differentiation via its receptor ST2L (17,18). In parallel with these observations, we demonstrate here that the protective effects of IL-33 also result from a shift from a Th1 to a Th2 immunological profile, which might be mediated by a direct expansion of a subset of CD4+ST2L+ T cells. Our data suggest induction of Th2 at least in part accounts for the beneficial effect of IL-33 administration. The reason why blockage of IL-4 activity did not completely abolish the therapeutic effect of IL-33 administration might be that other Th2 cytokines induced by IL-33 also play a role in TNBSinduced colitis, such as IL-13 (42,43). Although the molecular mechanism by which IL-33 shifts the balance between Th1 and Th2 cells is currently less clear, it has been reported that IL-33 could induce a Th2 immune response via DCs (44). Nevertheless, a recent study showed that IL-33 plays a pathogenic role in SAMP1/YitFc (SAMP) mice, a mixed Th1/Th2 immune response experimental colitis model of inflammatory bowel disease (24), and dextran sulfate sodium (DSS)-induced colitis (45). The different effect of IL-33 in TNBS-induced experimental colitis may result from discrepancy of Th1-type-dominated immune response.

Recently, the imbalance of Treg/ Th1–Th17 cell response was implicated in colitis (810). It was shown that an impaired Treg function is observed in ST2−/− mice (46), suggesting that IL-33/ST2 signaling might be involved in the development and function of Tregs. Indeed, we observed that IL-33 administration caused prominent induction of Tregs and suppressive cytokine IL-10. However, the expression of inflammatory cytokine IL-17 was not downregulated, which could be a result of IL-33 being a potent inducer of Th17 response (31). In parallel with up-regulated expression of Foxp3, the tolerogenic CD103+IDO+ DCs, which play a crucial role in reducing the pathological progression of CD and experimental colitis (21,22), were markedly increased in both MLN and lamina propria of rIL-33-treated mice. These results indicate that administration of rIL-33 favors Treg function probably by promoting CD103+ DC differentiation. Indeed, in this study, treatment of mice with rIL-33 resulted in increased ALDH1A1 and TSLP expression in IECs, which is critically implicated in the induction of tolerogenic CD103+ DC (22). As expected, our in vitro data showed that rIL-33 indirectly promoted the differentiation of tolerogenic CD103+ DCs and Tregs via acting on IECs. In addition, TSLP was also reported to induce Th2 immune type response (39).


In conclusion, our studies demonstrate that rIL-33 substantially ameliorates the development of TNBS-induced experimental colitis by a Th1-to-Th2/Treg switch, specifically depending on Treg expansion. These results suggest that IL-33 might offer an alternative treatment to our current approaches of managing CD.


The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.


  1. 1.

    Xavier RJ, Podolsky DK. (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–34.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Baumgart DC, Carding SR. (2007) Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–40.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Elson CO, Sartor RB, Tennyson GS, Riddell RH. (1995) Experimental models of inflammatory bowel disease. Gastroenterology. 109:1344–67.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Rovedatti L, et al. (2009) Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 58:1629–36.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Alex P, et al. (2009) Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 15:341–52.

    Article  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Hunter MM, McKay DM. (2004) Review article: helminths as therapeutic agents for inflammatory bowel disease. Aliment Pharmacol. Ther. 19:167–77.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. (2008) Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J. Pharmacol. Exp. Ther. 324:23–33.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Jager A, Kuchroo VK. (2010) Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand. J. Immunol. 72:173–84.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Fantini MC, et al. (2009) Smad7 controls resistance of colitogenic T cells to regulatory T cellmediated suppression. Gastroenterology. 136:1308–16, e1301–3.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Bai A, et al. (2009) All-trans retinoic acid downregulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J. Leukoc. Biol. 86:959–69.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Haraldsen G, Balogh J, Pollheimer J, Sponheim J, Kuchler AM. (2009) Interleukin-33: cytokine of dual function or novel alarmin? Trends Immunol. 30:227–33.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Schmitz J, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 23:479–90.

    CAS  Article  Google Scholar 

  13. 13.

    Xu D, et al. (1998) Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187:787–94.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Lohning M, et al. (1998) T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl. Acad. Sci. U. S. A. 95:6930–5.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Kurowska-Stolarska M, et al. (2008) IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 181:4780–90.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Kurowska-Stolarska M, et al. (2009) IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183:6469–77.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Miller AM, et al. (2008) IL-33 reduces the development of atherosclerosis. J. Exp. Med. 205:339–46.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Yin H, et al. (2010) IL-33 prolongs murine cardiac allograft survival through induction of TH2-type immune deviation. Transplantation. 89:1189–97.

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Turnquist HR, Thomson AW. (2009) IL-33 broadens its repertoire to affect DC. Eur. J. Immunol. 39:3292–5.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Rimoldi M, et al. (2005) Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat. Immunol. 6:507–14.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Matteoli G, et al. (2010) Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. Gut. 59:595–604.

    CAS  Article  PubMed  Google Scholar 

  22. 22.

    Iliev ID, et al. (2009) Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut. 58:1481–9.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Beltran CJ, et al. (2010) Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16:1097–107.

    Article  PubMed  Google Scholar 

  24. 24.

    Pastorelli L, et al. (2010) Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. U. S. A. 107:8017–22.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Hollenbach E, et al. (2005) Inhibition of RICK/ nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J. Biol. Chem. 280:14981–8.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Foligne B, et al. (2007) A key role of dendritic cells in probiotic functionality. PLoS One. 2:e313.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF. (2003) Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastro enterology. 125:1762–73.

    CAS  Article  Google Scholar 

  28. 28.

    Duan L, et al. (2010) High-mobility group box 1 promotes early acute allograft rejection by enhancing IL-6-dependent Th17 alloreactive response. Lab. Invest. 91:43–53.

    Article  PubMed  Google Scholar 

  29. 29.

    Liu H, Hu B, Xu D, Liew FY. (2003) CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J. Immunol. 171:5012–7.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Wakashin H, Hirose K, Iwamoto I, Nakajima H. (2009) Role of IL-23-Th17 cell axis in allergic airway inflammation. Int. Arch. Allergy Immunol. 149 (Suppl. 1):108–12.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Xu D, et al. (2008) IL-33 exacerbates antigeninduced arthritis by activating mast cells. Proc. Natl. Acad. Sci. U. S. A. 105:10913–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  32. 32.

    Mok MY, et al. (2010) Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 49:520–7.

    CAS  Article  Google Scholar 

  33. 33.

    Matsuba-Kitamura S, et al. (2010) Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int. Immunol. 22:479–89.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Alves-Filho JC, et al. (2010) Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat. Med. 16:708–12.

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. (2008) IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180:2443–9.

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Pastorelli L, De Salvo C, Cominelli MA, Vecchi M, Pizarro TT. (2011) Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation. Therap. Adv. Gastroenterol. 4:311–23.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Sponheim J, et al. (2010) Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts. Am. J. Pathol. 177:2804–15.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    Saenz SA, Taylor BC, Artis D. (2008) Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol. Rev. 226:172–90.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Taylor BC, et al. (2009) TSLP regulates intestinal immunity and inflammation in mouse models of helminth infection and colitis. J. Exp. Med. 206:655–67.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Caruso R, et al. (2009) Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology. 136:2270–9.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Casanova JL, Abel L. (2009) Revisiting Crohn’s disease as a primary immunodeficiency of macrophages. J. Exp. Med. 206:1839–43.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Danese S. (2011) IBD: of mice and men: shedding new light on IL-13 activity in IBD. Nat. Rev. Gastroenterol. Hepatol. 8:128–9.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Wilson MS, et al. (2011) Colitis and intestinal inflammation in IL10-/- mice results from IL-13Ralpha2-mediated attenuation of IL-13 activity. Gastroenterology. 140:254–64.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Rank MA, et al. (2009) IL-33-activated dendritic cells induce an atypical TH2-type response. J. Allergy Clin. Immunol. 123:1047–54.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Oboki K, et al. (2010) IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. U. S. A. 107:18581–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Zdravkovic N, Shahin A, Arsenijevic N, Lukic ML, Mensah-Brown EP. (2009) Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin. Mol. Immunol. 47:28–36.

    CAS  Article  PubMed  Google Scholar 

Download references


This work was supported by the National Natural Science Foundation of China (grant 81072440) and the Ministry of Science and Technology of China (grant 2007CB512402). The expert technical assistance of Ping Xiong and Yong Xu is gratefully acknowledged.

Author information



Corresponding authors

Correspondence to Feili Gong or Min Fang.

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Reprints and Permissions

About this article

Cite this article

Duan, L., Chen, J., Zhang, H. et al. Interleukin-33 Ameliorates Experimental Colitis through Promoting Th2/Foxp3+ Regulatory T-Cell Responses in Mice. Mol Med 18, 753–761 (2012).

Download citation


  • Experimental Colitis
  • Thymic Stromal Lymphopoietin (TSLP)
  • TNBS-induced Colitis
  • TNBS-treated Mice
  • Lamina Propria Mononuclear Cells (LPMCs)